Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 202512,384 Zelsuvmi units were dispensed by 4,942 unique prescribers during the third quarter of 2026, representing a 4% quarter-over-quarter increase in units dispens…